Bio B2B 〉 Selective Search Results
Your Selection Setting ：Marketing & Distribution；
Selective Search Results :
Pipeline & Platform 51 record(s)；
•iStat's technology platform, Methylation-Specific-PCR (MSP), is a proprietary DNA-based technology that detects tumor-specific gene methylation with high precision and accuracy.•Aberrant DNA methylation has known to be associated with human cancers through epigenetic gene silencing of tumor suppressor and DNA repair genes. iStat's MSP provides optimal solutions for physicians in cancer diagnosis
Taigexyn® (Nemonoxacin) is a novel broad spectrum antibiotic for treatment of bacterial infections. It belongs to a new class of antibiotics known as non-fluorinated quinolone. Taigexyn® was discovered by screening against antibiotic-resistant bacteria and thus has intrinsic activity against the resistant infection which is an increasingly severe problem worldwide.Launched in Taiwan in Dec
low-alcohol formulation (iLEF) platform
Intech Biopharm focus on new dosage, new combination, new delivery and high barrier generic drug development and manufacturing for respiratory therapy area. We are currently one of the leading companies, and the only one in Taiwan, that can provide and manufacture high barrier obstructive airway diseases drug and our competitive advantage are as follow: iLEF platform: It has a low-alcohol
INNOPHARMAX has extensive pharmaceutical R&D experience, with former researchers who worked for the Medical and Pharmaceutical Industry Technology and Development Center in Taiwan (which is the most influential pharmaceutical technology developing organization funded by the Taiwan government), INNOPHARMAX's R&D team has been highly praised by numerous pharmaceutical
TABP's transcriptional factor protein drugs are developed based on the fact that transcription factors can specifically act on the promoter of a gene. Comparable to monoclonal antibodies' specificity, the TABP's protein drugs can target to and regulate individual gene whose function people wish to change and by this means we can determined the proliferation and differentiation fate of cells. Advanced
CHAP™ is a self-owned technology of SciVision Biotech Inc. which provides the unique viscoelasticity of HYADERMIS™ Facial Dermal Implant series and HYAJOINT Plus™ Synovial Fluid Supplement. CHAP™ gel with water-retention characteristic, acts as a kind of natural sponge. It creates volume in the tissue, lubricates, and transports nutrients to and from cells.
TLC599 is our proprietary BioSeizer formulation of dexamethasone sodium phosphate (DSP) designed to provide sustained pain management over an extended period of three months or more. TLC599 has the potential to enable patients to receive both immediate and sustained benefit from the local delivery of a highly potent and clinically validated steroid that typically has a very short half-life. Our
Complete and Comprehensive Design/Production Capabilities
United Orthopedic has had the privilege of supplying world class orthopedic joint replacements, till now, had helped over 230 thousand suffering patients gain back their mobility and quality of life. Through cooperation with international orthopedic surgeons and institutes, United Orthopedic continue innovate and develop new techniques and design to fulfill the demand of modern orthopedic community
Six Genomic Technology Platforms
IVD Sequencing & NGS analysisSNP genotyping analysisGene Chip analysisFunctional genomics analysisClinical genomics analysisBioinformatics analysis
SB05 is an innovative composition of the established cytostatic drug paclitaxel combined with neutral and positive lipids. Due to the positively charged lipids, SB05 interacts with newly developing, negatively charged endothelial cells, which are especially required for the growth of tumor blood vessels. The SB05 paclitaxel component attacks the activated endothelial cells as they divide, thus targeting
Tmax of the current extended release tablets is too long, so children lose attention in learning when they start classes in the early morning.With both advantages of immediate and extended release, the unique multi-stages hot melt capsule releasing technology is able to become effective in early stage and sustainably release the drug to maintain the efficacy.The patented Oradur® formulation
The PixoTest® technology utilizes the lighting and image sensing module of the smartphone (or mobile device) to detect the color change reaction on the biochemical test strip (US patent granted). The image of the test strip is captured by the front camera of the smartphone and analyzed via the measurement algorithm to turn out a quantified or semi-quantified result. With the control on light
TiMAX Dental Service
In order to provide the most reliable and complete medical quality and service, TiMAX will also introduce the concept of brand service and incorporate advanced technology and dental products to the public.Through the innovative concept of an open surgery center structure and the technology of dental implants system, TiMAX Dental Service also makes use of Taiwan's excellent ICT industry technology
Zwitterionic interface processing technology
Zwitterionic anti-fouling technologyTechnical seed development observed from the cell membrane phospholipid arrangement.It can be applied to various fields.Difficult to hydrolysis is a characteristic that make Zwitterionic better than traditionally used materials like PEG or HEMA. After surface modification using Zwitterionic technology the interface is endbow with highly biocompatible.
Physio-Chemical LaboratoryChemistry faculty of RRL conducts wide range of tests to evaluate the Physical-chemical properties of pure and formulated Agrochemicals in compliance with EEC, OECD, OPPTS and SANCO guidelines.We follow internationally accepted methods like FAO, WHO, AOAC and CIPAC with strict compliance to OECD principles of Good Laboratory Practices.The areas of expertise include:5
Core Technology: Pegylation PlatformIn the field of protein drug design, the process of pegylation of the therapeutic protein preserves its biological activity by targeting the PEG polymer (polyethylene glycol) at a specific and defined region on the protein. PharmaEssentia's pegylation technology platform is designed to increase the protein drug's efficacy by prolonging its circulation in
ON101- New drug for diabetic foot ulcer healing
When a wound heals, it usually has three phases, the inflammatory phase, proliferative phase, and remodeling phase. The diabetes patients usually have multiple dysfunctional factors such as growth factors, cytokines, and collagen synthesis and these factors are crucial to wound healing. Furthermore, these patients often develop vascular stenosis or obstruction. As a result, blood supply to the wound
Small Molecule Drugs
ScinoPharm possesses a full range of chemistry capabilities and has extensive experience in synthesizing complex molecules. Depending on individual requirements, we develop new synthetic routes, or scale up and optimize processes based on the customer's technology. Our synthesis studies include structured Design of Experiment. (DoE) methods used to identify optimal conditions, factors that most
EG12014 Trastuzumab Biosimilar
Eirgenix aims to commercialize the first biosimilar product manufactured in Taiwan for the global market.Indication: HER2 Breast CancerExpected Product Launch: 2020Status: Phase 1 completed, BE established between EG12014 / EU & US HerceptinAdvantages of EG12014- The development of EG12014 follows EMA/FDA published guidance and past experience- EirGenix clinical study set up is considered an asset
All decellularization methods nowadays result in disruption of surface structure and partially change the composition. The decelluarization techniques from Horien biochemical technology has change that. It is an almost mature technique in our company. Horien Extracellular membrane, the membrane used in Guided Tissue Regeneration, is the first eco-friendly processed product releasing in Taiwan.
Patented CMx® Platform
Circulating Tumor Cells as Biomarker for Early Cancer Detection. Saving Life, It's in Our Blood.The CMx® Platform uses a biomimetic, lipid-bilayer coated microﬂuidic chip to capture these rare cells in peripheral blood. For colonrectal cancer, the test can be useful in cases of non-compliance with recommended colonoscopies or messy stool tests, and as a supplemental screening.
The laser beams are dynamically focused on the surface of microarray slide based on the auto-focusing function using the focus error signal (FES). The auto-focusing of the laser beam is controlled using the focusing voice coil motor (VCM) to adjust the vertical distance between the objective lens and the surface of the sample slide on the basis of the FES (= (A+C)−(B+D), where A, B, C, and D
Locking Plate System
Aplus, found in Taiwan in 2009, devotes itself to the research and development of orthopedic medical products. The Aplus team is known for its focus on, and innovation in, the orthopedic trauma field and the construction of a partnership among industry, academia, research circles, and the medical community.
TLC399 is our proprietary BioSeizer formulation of dexamethasone sodium phosphate (DSP) intended as an intravitreal, or in-eye, injection for the treatment of macular edema due to retinal vein occlusion. TLC399 in preclinical models has been shown to provide therapeutic levels of DSP in the eye for at least six months after a single administration. A Phase I/II safety trial has demonstrated encouraging
New combination for treating Sialorrhea
• Combination of two compounds with different Mechnism of Action to reduce the secreting of saliva.• First oral treatment for sialorrhoea of Parkinson's Disease.• Results of Phase IIa study, published in the 17th International Congress of Parkinson's Disease and Movement Disorders, shows efficacy and safety.
Cell selection adhesion technology
Cell selection adhesion technologyBase on the Zwitterionic coating surface, added with the charge-bias design, to have an effective resistance to various molecules include small-molecular, microorganisms Plankton and other cell adhesion, Further more gives the surface cell selection property.
There are 415 million diabetes patients in the world by 2015 and 10-15% of them have DFU which may lead to amputation or even death.ON101 is the first botanic drug for diabetic foot ulcer (DFU). Target Chronic DFU with Grade 1 or 2 per Wagner Ulcer Classification SystemFulfill the Global Unmet Medical Need in DFUClinical Status: Phase III Interim Analysis (2016)In compliance to US FDA &ldquo
● Ergonomically integrating ultrasonic probe, control switches and HD display in one device● Clever gel delivery with interrupting scan● Ideal companion for US-guide invasive procedure● Compatible with all ultrasound systems● Adjustable grip for easy scan of different body parts
OB318- New drug for anti-liver cancer
Liver is the largest and the most complex organ in human body. Liver cancer is more prevalent among Oriental people; it is a Top 3 cancer in Taiwan and China. Doctors’ treatment options, e.g. surgery, chemotherapy, radiotherapy, biological preparations, or combination therapy, etc., usually depend on disease staging, liver function, patient’s age, and physical condition. Compared to other
CellMax SMSEQ® PlatformAnalytical specificity of ≥99.999%CellMax Life's liquid biopsy blood test uses next generation sequencing technology to detect gene alterations.The patented technology, combined with years of research and development advancements enables CellMax to offer an extremely cost effective and liquid biopsy, profiling 73 genes from circulating tumor DNA (ctDNA), to identify
Poor solubility and high toxicity are significant problems with many new promising therapeutic approaches in oncology. By using TLC's lipid-based technology to improve solubility characteristics of a new derivative from a well-known chemotherapeutic drug (camptothecin), we were able to enhance its clinical development potential. In addition, TLC388 shows
Isoniazid without liver toxicity
1. The common Tuberculosis (TB) drug Isoniazid has the most side effect of hepatotoxicity among all drugs, which is considered to be the major barrier of TB treatment.2. Isoniazid with new formulation has no hepatotoxicity due to the special excipient.
MS-20 is a mixture of soy fermentation metabolites which is produced in strictly controlled fermenter and with carefully chosen microorganisms that mimics human intestinal environment.The manufacturing and R&D procedures of Chemo Young follow the international regulations.MS-20 was approved as new drug by TFDA in 2011.MS-20 acts as an immunemodulator and probiotics to improve immunity and
TAH4411 Antiemetic Oral Thin Film
TAH4411 oral dissolving film (ODF) is a new formulation of a selective 5-HT3 receptor antagonist which blocks stimulation on both peripherally located vagal nerve terminals and centrally located receptors in the chemoreceptor trigger zone of the area postrema.This new formulation provides equivalent amount of the active ingredient as in Zofran® tablets and Zofran® OD tablets, but with a potential
Zelnite® Solution for Injection is developed for treatment or prevention of selenium deficiency that cannot be offset by intake from food sources, or in patients receiving parenteral nutrition.
Injectable Manufacturing Services
Already the leader in providing oncological APIs to regulated markets worldwide, ScinoPharm is poised to extend the service to offer finished dosage form of injectable products. With the completion of injectable plant in Tainan campus in Taiwan and combining the API capability, ScinoPharm is able to provide integrated solutions for one-stop shopping of injectable products in a flexible, reliable and
Friendly GUI interface for reading and displaying 16 bit TIFF image files.GenePix Array List (GAL) file or MSK file. Optical image multi-block circular array of fluorescent spots. Tiff image generated by the automatic selection of slide bits on the fluorescence spots.Adjustable image brightness and contrast.Display histogram distribution of fluorescent reaction of wavelengths 532nm and/or
TLC's own formulation of liposome encapsulated doxorubicin effectively reduces the side effects of doxorubicin and broadens its indications.
Multiple-Phasic Release Technology (MPRT)
Through Orient Pharma's patented technology, incompatible ingredients or drugs with different release profiles can be enclosed in a single capsule or tablet for the development of new drugs.
AmCAD-UO is an innovative solution to assist physicians evaluating the risk of Obstructive Sleep Apnea (OSA) syndrome.The solution consists of a positioning system and a computer-assisted detection software device.The evaluation process is performed on awake patients and takes no more than 10 minutes to get the results.The entire process is objective, accurate, cost-effective and safe and is expected
TAH9922 ADHD Oral Solution
TAH9922 is an once-daily, liquid ADHD treatment option. It is a flavored, immediate release ADHD treatment option for patients ages 6 and above. Dosing can be tailored to the treatment's need.Uniqueness:• Better Palatability• Improved patient compliance via non-invasive, painless and simple application
ScinoPharm provides comprehensive peptide synthesis technologies with full analytical and regulatory support. With rich knowledge and expertise in peptide synthesis and proprietary platform technologies, ScinoPharm can design and develop higher yield processes for larger-scale peptides that are scalable and more cost effective, ensuring faster time-to-market.Peptide Synthesis CapabilitiesSynthesis
TLC178 is a formulation of vinorelbine loaded into liposomes, designed to reduce toxicity and improve efficacy with fewer administrations.We are initially developing TLC178 for pediatric RMS. The increased specificity of TLC178 for tumor versus non tumor tissue through the use of our NanoX technology, which utilizes enhanced permeability and retention effects, will enable greater dose intensity
Multi-day Transdermal Drug Delivery (MTDD)
Matrix type of design resolves API to form API/Adhesive patch, which is embedded in between Backing Layer and Release Liner. The API containing side of the patch can be adhered to the skin by tearing off the Release Liner. The patch can be designed as double layers for 1-2 days use or single layer for multiple days use.
TRIA11 is a biosimilar indicated for osteoporosis. The current global sales of the original product reaches to $1.7 billion. An injection pen is also developed to enhance the convenience of use. TRIA11 is planned to launch in EU first, and TSH Biopharm has consulted EMA for the development plan. TRIA11 is expected to move into clinical stage by the end of 2019.
TLC590 brings sustained release delivery technology to the common anesthetic ropivacaine, with the goal of reducing the frequency of administration for local anesthesia for post-surgical pain. More effective pain relief may also allow patients to avoid the problems of opioid therapies often used for the treatment of post-surgical pain.
AmCAD-CA, specially designed for microscopy cytology is the only commercially available software specifically designed for cytopathology analysis. AmCAD-CA features visualization and quantification of clinical characteristics, such as nucleus size, circularity, polarity and elongation, nuclear-cytoplasm ratio, inclusion bodies, etc, for cytology microscopic images, aiding professionals in biological
NanoX™ technology uses nanoparticles coated with the compound polyethylene glycol to reduce uptake by phagocytic cells of the immune system. This prolongs circulation in the body, allowing a drug to predominantly accumulate at particular disease sites such as tumors. Therapies based on NanoX™ technology can also make use of additional molecular coatings to help nanoparticles to accumulate
TLC is using antibodies and antibody fragments attached to lipid encapsulated drugs to develop more effective therapies in oncology. These antibody-linked nanomedicines actively target specific tissues using binding interactions between a specific antibody and a target antigen on the surface of a particular cell type. Compared with passively targeted therapies, these nanomedicines are better able to
TLC's BioSeizer™ technology uses multi-layer lipid membranes to encapsulate therapeutically active molecules, providing an exceptionally long duration of drug release. BioSeizer™ nanoparticles are precisely designed to release the payload at a constant rate as each layer collapses over time. In addition, BioSeizer™ technology works to extend the duration of therapies
By encapsulating molecules with poor solubility in polymeric micelle nanoparticles, TLC's technology can increase the solubility of a drug. This allows a larger quantity to be delivered in a single dose, which can enable new forms of administration. For molecules that are too insoluble to be practical as stand-alone therapies, lipid encapsulation may be the key to generating an entirely new type